Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shawn Malone

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2002
Improving the consistency in cervical esophageal target volume definition by special trainingPatricia Tai, Jake Van Dyk, Jerry Battista, et al.
European Urology|March 9, 2023
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 TrialSoumyajit Roy, Yilun Sun, Scott C Morgan, et al.
Cancer|September 4, 2025
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based studyDavid-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
The Lancet. Oncology|May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
JNCI Cancer Spectrum|December 20, 2021
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate CancerChristopher J D Wallis, Shawn Malone, Ilias Cagiannos, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trialSoumyajit Roy, Fred Saad, Yilun Sun, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2002
Improving the consistency in cervical esophageal target volume definition by special trainingPatricia Tai, Jake Van Dyk, Jerry Battista, et al.
European Urology|March 9, 2023
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 TrialSoumyajit Roy, Yilun Sun, Scott C Morgan, et al.
Cancer|September 4, 2025
Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based studyDavid-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari, et al.
The Lancet. Oncology|May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 28, 2020
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialistsSebastien J Hotte, Antonio Finelli, Kim N Chi, et al.
JNCI Cancer Spectrum|December 20, 2021
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate CancerChristopher J D Wallis, Shawn Malone, Ilias Cagiannos, et al.
Pageof 12